劳拉替尼100Loratinib

Indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) or ROS1 positivity.

Recommended Dose: 100 mg orally once daily.

Concomitant use with strong CYP3A inducers.

Central Nervous System (CNS) Effects: Interrupt treatment and resume at the same or reduced dose based on symptom severity. Hyperlipidemia, Atrioventricular Block: Interrupt treatment or reduce the dose as appropriate. Interstitial Lung Disease (ILD)/Pneumonitis: Discontinue the medication immediately in patients who develop ILD/pneumonitis. Embryo-Fetal Toxicity: May cause fetal harm; inform patients of the potential risk to the fetus.

Edema, peripheral neuropathy, cognitive effects, dyspnea, fatigue, weight gain, arthralgia, mood effects, and headache.

30 tablets per bottle.

Store in a cool, dry place below 30℃, protected from light. Keep out of the reach of children.